GlaxoSmithKline Revises US Labeling For Avandia

GlaxoSmithKline announced that it is implementing changes to the US product label for Avandia® (rosiglitazone maleate), based on an extensive and thorough review by the FDA of myocardial ischemia data on Avandia, the most widely studied oral anti diabetic medicine available. [click link for full article]

More: continued here

Filed under: Clinical Trials on November 20th, 2007